MedTrace Logo

Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer

NCT03595644 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2021-04-08

No results posted yet for this study

Summary

This is a Prospective, Multicenter, Randomized Controlled study to evaluate Stereotactic Body Radiation Therapy (SBRT) as a potential treatment for stage IV non-small cell lung cancer (NSCLC) that has a mutated epidermal growth factor receptor (EGFR) and has been receiving treatment with a targeted agent such as gefitinib, erlotinib and icotinib.

Conditions

  • Stage IV Non-small Cell Lung Cancer

Interventions

RADIATION

SBRT+TKI

Received SBRT after three months after EGFR-TKI treatment

DRUG

TKI

Received EGFR-TKI treatment

Sponsors & Collaborators

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    collaborator OTHER

  • Renmin Hospital of Wuhan University

    collaborator OTHER

  • Wuhan University

    collaborator OTHER

  • Hubei Cancer Hospital

    collaborator OTHER

  • Tongji Hospital

    lead OTHER

Principal Investigators

  • li Zhang, MD,PhD · Tongji Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-12
Primary Completion
2019-06-10
Completion
2020-12-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03595644 on ClinicalTrials.gov